New Survival Data Keeps Roche Ahead In TIGIT Immunotherapy Race

But Can It Really Challenge Keytruda Dominance?

 
• By Andrew McConaghie
  
Roche_Basel
Despite being a leader in cancer, Roche is still trailing Merck & Co's dominant position in immunotherapy. • Source: Roche
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip